<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804828</url>
  </required_header>
  <id_info>
    <org_study_id>GW140146</org_study_id>
    <nct_id>NCT02804828</nct_id>
  </id_info>
  <brief_title>Mitochondrial Cocktail for Gulf War Illness</brief_title>
  <official_title>Beyond Benefits of Q10: Mitochondrial Cocktail for Gulf War Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop preliminary evidence, such as effect size and
      variance estimates, to guide successful conduct of a properly-powered clinical trial to
      assess the benefit of a mitochondrial cocktail (incorporating individualization of treatment)
      in Gulf War illness (GWI).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in single item General Self-Rated Health Visual Analog Scale from baseline to 6 months</measure>
    <time_frame>0, 3, 6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent improved on Gulf War Illness Modified Lower Extremity Performance Score/timed chair rises from 0 to 6 months</measure>
    <time_frame>6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. placebo</measure>
    <time_frame>0, 3, 6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change of CoQ10 and Vitamin E levels, comparing active treatment to placebo</measure>
    <time_frame>6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Gulf War Syndrome</condition>
  <condition>Persian Gulf Syndrome</condition>
  <condition>Mitochondrial Disorders</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Individualized mitochondrial cocktail</intervention_name>
    <description>Nutrient cocktail comprising: B-vitamins, carnitine, alpha lipoic acid, coq10, vitamin C, vitamin E, and omega 3 fatty acids. Depending on the participant, citrulline/arginine or methionine.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 months for the double-blind phase</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet symptom criteria for Gulf War illness with BOTH the Centers for Disease Control
             and Prevention (CDC) Criteria (persistent symptoms in at least 2 of 3 designated
             symptom domains of fatigue/sleep, mood/cognition, and musculoskeletal) and Kansas
             Criteria (score a moderate or severe rating in at least 3 of the 6 symptom domains of
             fatigue, pain, neurological/cognitive/mood, skin, GI and respiratory).

        Exclusion Criteria:

          -  Have conditions like multiple sclerosis or lupus that can produce similar symptoms and
             be confused for Gulf War illness.

          -  Participating in a concurrent treatment trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janis B. Ritchie, BSN</last_name>
    <phone>858-558-4950</phone>
    <email>jbritchie@ucsd.edu</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Beatrice Golomb</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Persian Gulf Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

